Zimmer Biomet Holdings Inc. (NYSE:ZBH) finished Friday with a subtraction of -$0.33 to close at $127.50, a downside of -0.26 percent. An average of 753,380 shares of common stock have been traded in the last five days. There was a gain of $0.71 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 1,299,025 shares traded, while the 50-day average volume stands at 1,233,322.
ZBH stock has increased by 6.16% in the last month. The company shares reached their 1-month lowest point of $120.35 on 12/06/22. With the stock rallying to its 52-week high on 04/21/22, shares of the company touched a low of $100.39 and a high of $135.05 in 52 weeks. It has reached a new high 5 times so far this year and achieved 3.45% or $0.46 in price. In spite of this, the price is down -5.59% from the 52-week high.
ZBH stock investors should be aware that Zimmer Biomet Holdings Inc. (ZBH) stock had its last reported insider trading activity 18 days ago on Dec 13. In this transaction, the insider spent $1,482,079. Pres, Europe, M. East & Africa, VAN ZUILEN WILFRED, disposed of 531 shares at a price of $105.22 on Jul 05. The insider now owns more than $55,870 worth of shares. Prior to that, Sr. VP/Gen Counsel/Secretary Phipps Chad F went on to Sale 35,149 shares at $121.97 each on Mar 17. An amount of $4,287,248 was transacted.
Zimmer Biomet Holdings Inc. (ZBH) has a trailing price-to-earnings (P/E) ratio of 79.34. The stock’s beta is 1.04. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.74, the price-to-book (PB) ratio at 2.18, and the price-to-cash flow ratio at 26.69.
The company has a payout ratio of 72.50%. The company’s most recent quarterly dividend payment was $0.24 a share, without any change from last year. Its latest increase dividend $0.02 reported on Wednesday February 24 2016.
The quick ratio of Zimmer Biomet Holdings Inc. for the three months ended June 29 was 1.00, and the current ratio was 2.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.41 and a total debt to equity ratio of 0.47 for the quarter ending June 29. Its gross profit as reported stood at $5.5 billion compared to revenue of $7.84 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Zimmer Biomet Holdings Inc.’s return on assets was 1.30%.
For the three-month period that ended June 29, Zimmer Biomet Holdings Inc. had $5.06 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $194.0 million in the quarter, while revenues of $153.7 million were grew 24.95%. The analyst consensus anticipated Zimmer Biomet Holdings Inc.’s latest quarter earnings to come in at $1.64 per share, but it turned out to be $1.82, a 11.00% surprise. For the quarter, EBITDA amounted to $476.7 million. Shareholders own equity worth $209.85 million.
From a technical analysis perspective, let’s take a brief look at Zimmer Biomet Holdings Inc. (ZBH) price momentum. RSI 9-day as of the close on 30 December was 61.68%, suggesting the stock is Neutral, with historical volatility in this time frame at 12.13%.
As of today, ZBH’s price is $127.06 +0.56% or $0.71 from its 5-day moving average. ZBH is currently trading +3.36% higher than its 20-day SMA and +13.34% higher than its 100-day SMA. However, the stock’s current price level is +17.92% above the SMA50 and +4.52% above the SMA200.
The stochastic %K and %D were 47.96% and 49.86%, respectively, and the average true range (ATR) was 2.25. With the 14-day stochastic at 53.45% and the average true range at 2.38, the RSI (14) stands at 62.50%. The stock has reached 0.49 on the 9-day MACD Oscillator while the 14-day reading was at 0.32.
Wells Fargo upgraded Zimmer Biomet Holdings Inc. (NYSE: ZBH) to a an Equal weight rating in its most recent analyst report. Previously, the stock was rated as an Underweight. The consensus rating for Zimmer Biomet Holdings Inc. (ZBH) among analysts is Hold. According to current brokerage recommendations, 2 brokerage firms advise that investors sell ZBH, while 17 suggest investors hold. There are 2 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 6 others rate it as a “buy”.